Ropes & Gray advised Acumen Pharmaceuticals in a global non-exclusive collaboration and license agreement with Halozyme Therapeutics. Acumen will explore the potential use of ENHANZE subcutaneous drug delivery technology with Acumen’s clinical stage monoclonal antibody to target amyloid beta oligomers for the treatment of early Alzheimer’s disease. The transaction was announced on November 6.

Under the agreement, in return for an upfront payment to Halozyme and other considerations, Acumen will receive non-exclusive rights to ENHANZE. Acumen is obligated to make future payments to Halozyme, subject to achievement of specified development, regulatory and sales milestones. Halozyme will also be entitled to receive royalties on sales of commercialized medicines using the ENHANZE delivery technology.

The Ropes & Gray team included life sciences transactions partner Hannah England and intellectual property transactions associate Parker Elliot.